Novartis India Outlines Strategic Shift Post ChrysCapital Acquisition and Key M&A
Novartis India Ltd · Investor Presentation · 11 Sept 2026, 9:20 pm
Novartis India Outlines Strategic Shift Post ChrysCapital Acquisition and Key M&A Following ChrysCapital Group's acquisition of a 70.68% stake from Novartis AG at ₹860.64 per share on 29th Jul'26, Novartis India Limited (NIL) outlined its strategic transformation. NIL is transitioning from partner-led distribution to an in-house model with a 900+ member field force covering ~150,000 HCPs, incurring one-time transition costs across Q2-Q4 FY27. Expanding its portfolio, NIL acquired the 'Minipress' trademark from Pfizer for ₹1,250 Cr and entered an exclusive ₹10 Cr in-licensing pact for retina drugs Accentrix and Pagenax. NIL will rebrand within 120 days.
Original exchange filing (PDF)
More announcements from Novartis India Ltd
- Transcript of the Earnings Call held on Wednesday, November 04, 2026. · 06 Nov 2026
- Submission of the Letter of Offer in connection with the proposed Rights Issue of the Partly Paid-up Equity Shares of the Company. · 06 Nov 2026
- Intimation is hereby given that the record date for determining the rights entitlement for the Rights Issue of partly paid-up shares of the Company shall be Wednesday, November 11, 2026. · 05 Nov 2026
- Outcome of the Board Meeting held today i.e. November 04, 2026 · 05 Nov 2026
- Outcome of the meeting of the Rights Issue Committee held today i.e. November 04, 2026 · 05 Nov 2026
- Intimation of the Audio Recording of the Earnings Call for the Unaudited Financial Results for the quarter and half year ended September 30, 2026, held today i.e. on Wednesday, November 04, 2026. · 04 Nov 2026
- Intimation of the Integrated Unaudited Financial Results for the quarter and half year ended September 30, 2026. · 04 Nov 2026
- Press Release - Unaudited Financial Results for the quarter and half year ended September 30, 2026. · 04 Nov 2026
